A detailed history of Ameritas Investment Partners, Inc. transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Ameritas Investment Partners, Inc. holds 9,760 shares of NTLA stock, worth $139,568. This represents 0.01% of its overall portfolio holdings.

Number of Shares
9,760
Previous 9,133 6.87%
Holding current value
$139,568
Previous $204,000 1.96%
% of portfolio
0.01%
Previous 0.01%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$19.72 - $27.36 $12,364 - $17,154
627 Added 6.87%
9,760 $200,000
Q4 2023

Feb 14, 2024

BUY
$23.16 - $32.34 $8,499 - $11,868
367 Added 4.19%
9,133 $278,000
Q3 2023

Nov 13, 2023

BUY
$31.62 - $45.78 $46,797 - $67,754
1,480 Added 20.31%
8,766 $277,000
Q2 2023

Aug 11, 2023

BUY
$34.58 - $46.03 $26,107 - $34,752
755 Added 11.56%
7,286 $297,000
Q1 2023

May 10, 2023

SELL
$33.3 - $44.82 $8,991 - $12,101
-270 Reduced 3.97%
6,531 $243,000
Q4 2022

Feb 13, 2023

BUY
$33.21 - $62.69 $29,523 - $55,731
889 Added 15.04%
6,801 $237,000
Q3 2022

Nov 14, 2022

BUY
$53.92 - $71.7 $13,803 - $18,355
256 Added 4.53%
5,912 $330,000
Q2 2022

Aug 12, 2022

BUY
$38.49 - $76.21 $10,623 - $21,033
276 Added 5.13%
5,656 $292,000
Q3 2021

Nov 15, 2021

BUY
$132.37 - $176.78 $49,109 - $65,585
371 Added 7.41%
5,380 $722,000
Q2 2021

Aug 06, 2021

BUY
$60.88 - $161.91 $33,301 - $88,564
547 Added 12.26%
5,009 $811,000
Q1 2021

May 14, 2021

BUY
$46.59 - $83.68 $8,945 - $16,066
192 Added 4.5%
4,462 $358,000
Q3 2020

Nov 13, 2020

BUY
$17.47 - $24.93 $6,953 - $9,922
398 Added 10.28%
4,270 $85,000
Q2 2020

Aug 05, 2020

BUY
$11.14 - $22.87 $9,201 - $18,890
826 Added 27.12%
3,872 $81,000
Q3 2019

Nov 14, 2019

BUY
$13.07 - $18.51 $6,077 - $8,607
465 Added 18.02%
3,046 $41,000
Q2 2018

Aug 13, 2018

BUY
$20.02 - $30.79 $26,746 - $41,135
1,336 Added 107.31%
2,581 $71,000
Q2 2017

Aug 15, 2017

BUY
N/A
1,245
1,245 $20,000

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $1.09B
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Ameritas Investment Partners, Inc. Portfolio

Follow Ameritas Investment Partners, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ameritas Investment Partners, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Ameritas Investment Partners, Inc. with notifications on news.